Short Interest in Evogene Ltd. (NASDAQ:EVGN) Grows By 154.6%

Evogene Ltd. (NASDAQ:EVGN) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 313,620 shares, an increase of 154.6% from the May 31st total of 123,199 shares. Currently, 3.9% of the shares of the stock are sold short. Based on an average trading volume of 2,420,901 shares, the days-to-cover ratio is currently 0.1 days.

Evogene Stock Up 1.1%

Shares of EVGN opened at $0.39 on Monday. The stock has a market cap of $3.43 million, a price-to-earnings ratio of -0.28 and a beta of 1.35. Evogene has a 12 month low of $0.37 and a 12 month high of $1.50. The company has a 50-day moving average price of $0.67 and a two-hundred day moving average price of $0.85.

Evogene (NASDAQ:EVGN) last released its quarterly earnings data on Saturday, May 16th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.33). Evogene had a negative net margin of 638.12% and a negative return on equity of 158.82%. The company had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.35 million.

Institutional Trading of Evogene

Institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in Evogene during the fourth quarter worth $25,000. Citadel Advisors LLC lifted its holdings in shares of Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 36,206 shares during the period. Finally, Jane Street Group LLC boosted its stake in shares of Evogene by 58.0% in the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,387 shares in the last quarter. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.